替普瑞酮联合埃索美拉唑治疗反流性食管炎的临床疗效观察

目的观察替普瑞酮联合埃索美拉唑治疗反流性食管炎的临床疗效。方法经内镜下确诊反流性食管炎患者96例，随机分两组，均口服埃索美拉唑和多潘立酮，其中观察组加用替普瑞酮，对照组加用硫糖铝。疗程均为8周。对比观察临床有效率、胃镜下愈合率和不良反应，以及1年后随访结果。结果临床症状缓懈时间和总有效率观察组分别为（9．3±3．5）d和95．8％，显著优于对照组的（15．7±5．2）d和81．2％（均P〈0．05）；观察组内镜下食管炎疗效总有效率为93．8％、1年复发率为8．3％，分别优于对照组的81．2％、22．9％（均P〈0．05）；两组有头痛、恶心反应各1例，无严重不良反应发生。结论替普瑞酮联合埃索美拉唑治疗反流性食管炎有更好的近期疗效和较低的复发率。

Clinical observation on the curative effect of teprenone combined with esomeprazole for reflux esophagitis

Objective To investigate the curative effect of Teprenone combined with esomeprazole for reflux esophagitis. Methods 96 cases of reflux esophagitis comfirmed by endoscope were obtained and divied into observation group and control group randomly. Both groups were offered with esomeprazole and motilium. Teprenone was added to the observation group and sucralfate was added to the control group. Clinical effective rate,healing rate,adverse reactions and one-year follow up were observed closely after the course of 8 weeks. Results The relief time of clinical symptom and total effective rate in the observation group were(9.3 ±3.5)d and 95.8% respectively,which were significantly higher than those in the control group(P ＜0.05). Endoscopic effective rate was 93.8% in observation group and 81.2% in control group respectively and statistically significant difference was observed (P ＜0. 05). Recurrence rate after one year in the observation group was 8. 3% ,which was significantly lower than in the control group (P ＜ 0.05). One case of headache and nausea occurred in both groups but no severe adverse reaction was observed. Conclusion Teprenone combined with esomeprazole were more effective and more likely to approach the complete cure for reflux esophagitis.